Skip to main content

Table 2 MCDA criteria, Test Anova, SLAM, AHP weights and the results of sensitivity analysis

From: Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis

  Test Anova SLAM AHP weights VIP min VIP max Max Regret
Indication uniquenes 0.8529 10 2.31% 0.12 0.5 0.87
Disease rarity 0.4815 8 3.34% 0.3 0.66 0.69
Disease severity 0.4837 9 3.38% 0.23 0.5 0.76
Adv.tech. 0.7574 12 0.42% 0 0.05 1.00
Manufacturing technology 0.2169 13 0.23% 0 0.02 1.00
Therapeutic alternative 0.3666 4 8.56% 0.5 0.67 0.5
Sci. evid. Clin.eff 0.2546 1 14.76% 0.98 1.00 0.00
Benefits from use of medicine (safety aspects) 0.0071* 3 12.68% 0.5 0.81 0.5
Cost effectiveness analysis 0.0747 5 9.86% 0.48 1.00 0.52
Budget impact analysis 0.646 6 10.26% 0.44 0.58 0.56
Therapy cost 0.2937 2 17.60% 0.5 0.82 0.5
HTA recommendations issued elsewhere 0.0691 7 11.88% 0.48 0.83 0.51
Rationalization analysis 0.0176* 11 4.73% 0.13 0.5 0.87
  1. SLAM Simple Linear Additive Model, AHP Analytic Hierarchy Process, VIP Variable Interdependent Parameters, Sci. evid. clin.eff Scientific evidence for clinical efficiency, Adv.tech. Advancement of technology
  2. *statistical significance at p-value (≤ 0.05)